Brief: Teva & Medincell Announce FDA Approval Of Uzedy (Risperidone) Extended-Release Injectable Suspension For The Treatment Of Schizophrenia In Adults

Medincell SA

29/04/2023 24:27

April 28 (Reuters) - Teva Pharmaceutical Industries Ltd
 TEVA.TA :
    * TEVA AND MEDINCELL ANNOUNCE FDA APPROVAL OF UZEDY™
(RISPERIDONE)
EXTENDED-RELEASE INJECTABLE SUSPENSION, A LONG-ACTING
SUBCUTANEOUS ATYPICAL ANTIPSYCHOTIC INJECTION, FOR THE TREATMENT
OF SCHIZOPHRENIA IN ADULTS
    * TEVA PHARMACEUTICAL INDUSTRIES - IN A PHASE 3 CLINICAL
TRIAL,
UZEDY DEMONSTRATED UP TO 80% REDUCTION IN RISK OF SCHIZOPHRENIA
RELAPSE VERSUS PLACEBO
    * SAYS UZEDY WILL BE AVAILABLE IN U.S. IN COMING WEEKS
    * WHOLESALE ACQUISITION COST FOR UZEDY RANGES FROM $1,232 TO
$3,080 PER MONTH DEPENDING ON DOSAGE STRENGTH

Source text for Eikon:  ID:nBw8bgWx0a 
Further company coverage:  TEVA.TA 

 ((Reuters.Briefs@thomsonreuters.com;))